site stats

Astellas mycamine

WebAstellas Pharma US, Inc. announced today the launch and availability of their newest systemic anti-fungal agent MYCAMINE™ (micafungin sodium) for Injection to hospitals nationwide. The U.S. Food... WebDec 15, 2014 · PHILADELPHIA – Pharmaceutical company Astellas Pharma US, Inc., will pay $7.3 million to resolve allegations that it violated the False Claims Act in connection with its marketing and promoting of the drug Mycamine for pediatric use. The settlement was announced today by United States Attorney Zane David Memeger and the Justice …

Pediatric Focused Safety Review: Mycamine (micafungin)

WebJan 24, 2024 · Astellas reported Mycamine ® sales of JPY 18.9 billion (USD 135 million) for the year ending March 31, 2024. The announcement comes after Sandoz successfully … Web• The efficacy of Micafungin for Injection against infections caused by fungi other than : Candida : has not been established. Additional pediatric use information is approved for Astellas Pharma US, Inc.’s Mycamine (micafungin for injection). However, due to Astellas Pharma US., Inc.’s marketing exclusivity rights, this drug product is ... hotel hassler rome italy https://billmoor.com

Astellas Transfers MYCAMINE® Product Worldwide Markets …

WebJan 24, 2024 · Novartis division Sandoz has entered an agreement to buy the global product rights for the antifungal agent Mycamine (micafungin sodium) from Japanese company Astellas Pharma. Under the agreement, Astellas Pharma will receive an upfront of $62.5m to 75m depending on the transaction closing date, along with milestone payments based … WebJan 24, 2024 · Astellas reported Mycamine ® sales of JPY 18.9 billion (USD 135 million) for the year ending March 31, 2024. The announcement comes after Sandoz successfully … WebJan 23, 2024 · MYCAMINE ®. (Generic Name: micafungin sodium/product name in Japan: FUNGUARD ®) Sales of the product. JPY 18.9 billion (fiscal year ended March 31, 2024) Astellas is reviewing potential financial … pub in chippenham

Sandoz announces agreement to acquire leading antifungal agent Mycamine ...

Category:Mycamine® Astellas Pharma Philippines Inc.

Tags:Astellas mycamine

Astellas mycamine

HIGHLIGHTS OF PRESCRIBING INFORMATION

WebMYCAMINE is contraindicated in persons with known hypersensitivity to micafungin sodium, any component of MYCAMINE, or other echinocandins. (4) WARNINGS AND PRECAUTIONS • • • • • ADVERSE REACTIONS • • To report SUSPECTED ADVERSE REACTIONS, contact Astellas Pharma US, Inc. at 1-800-727-7003 or FDA at 1-800-FDA … WebJan 28, 2024 · FDA Approved: Yes (First approved March 16, 2005) Brand name: Mycamine. Generic name: micafungin sodium. Dosage form: for Injection. Company: Astellas Pharma US, Inc. Treatment for: Esophageal Candidiasis, Fungal Infection Prophylaxis, Candidemia. Mycamine (micafungin sodium) is an echinocandin antifungal …

Astellas mycamine

Did you know?

Webeffectiveness of MYCAMINE in patients younger than four months of age have not been established. The overall safety of MYCAMINE was assessed in 479 patients, ages three days through 16 years, who received at least one dose of MYCAMINE in 11 separate clinical trials. The mean treatment duration was 24.8 days. WebAstellas Stock Replacement Program For Mycamine, a patient assistance program provided by Astellas Pharma Inc., offers Mycamine at no cost to those who are eligible for the program. Eligibility is based off of the following requirements: You must be a citizen of the United States or its Territories.

WebMar 31, 2024 · Astellas reported Mycamine sales of US$135 million for the year ending March 31, 2024. Mycamine is indicated for treatment of invasive candidiasis and espophageal candidiasis, which are currently ... WebJun 24, 2013 · Astellas Pharma US, Inc., located in Northbrook, Illinois, is a U.S. affiliate of Tokyo -based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of...

WebMar 31, 2024 · Mycamine is indicated for: Adults, adolescents ≥ 16 years of age and elderly treatment of invasive candidiasis; treatment of oesophageal candidiasis in patients for whom intravenous therapy is appropriate; WebAstellas Hong Kong. The Company was established in 1995 with the name of Fujisawa Hong Kong, Ltd., a wholly-owned subsidiary of Fujisawa Taiwan Co., Ltd. Read More. …

WebJan 23, 2024 · MYCAMINE ® (Generic Name: micafungin sodium/product name in Japan: FUNGUARD ®) Sales of the product JPY 18.9 billion (fiscal year ended March 31, 2024) …

WebJan 8, 2024 · NORTHBROOK, Ill., Jan. 8, 2024 / PRNewswire / -- Astellas Pharma Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for MYCAMINE ® (micafungin for injection) in support of the treatment of Candidemia, Acute Disseminated Candidiasis, Candida … hotel hasselt holiday innWebJan 10, 2024 · Mycamine is an antifungal medication that fights infections caused by fungus. Mycamine is used to treat infections caused by the Candida fungus. It is also used to prevent Candida fungal infections in stem cell transplant patients. Mycamine is for use in adults and pediatric patients. pub in churchillWeb3 . Background Drug Information: Mycamine (micafungin) • Therapeutic Category: echinocandin • Sponsor: Astellas Pharma, Inc. • Indication: In adults and pediatric patients 4 months hotel haselbourgWebAstellas Pharma US, Inc. announced today the availability of their antifungal agent MYCAMINE® (micafungin sodium) for injection in a 100mg vial format. Approved in 2005 … hotel harrys abano termeWebJan 23, 2024 · MYCAMINE ® (Generic Name: micafungin sodium/product name in Japan: FUNGUARD ®) Sales of the product JPY 18.9 billion (fiscal year ended March 31, 2024) Astellas is reviewing potential... pub in clitheroeWebJan 24, 2024 · Astellas reported Mycamine ® sales of JPY 18.9 billion (USD 135 million) for the year ending March 31, 2024. The announcement comes after Sandoz successfully completed the acquisition of GSK’s global cephalosporins portfolio in October 2024. pub in clifton hampdenWebJan 24, 2024 · Astellas reported Mycamine sales of $135 million for the year ending Mar 31, 2024. Shares of Novartis have gained 7.7% in the past year compared with the industry’s increase of 15.5%. Zacks... pub in clifton on teme